Skip to content

Geron GERN Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

Immunome logo
ImmunomeIMNM
$0
Celcuity logo
CelcuityCELC
$31K-99.4%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's proceeds from warrant exercises?
Geron (GERN) reported proceeds from warrant exercises of $1.51M in Q1 2026.
What is the long-term trend for Geron's proceeds from warrant exercises?
Over 2 years (2023 to 2025), Geron's proceeds from warrant exercises has grown at a -100.0% compound annual growth rate (CAGR), from $105.91M to $0.
What does proceeds from warrant exercises mean?
This metric tracks the cash proceeds received by the company when holders of outstanding warrants exercise their right to purchase common stock at a predetermined strike price. It represents a non-dilutive or secondary source of capital that occurs as existing financial instruments are converted into equity. An increase in these proceeds typically indicates investor confidence in the company's long-term valuation and future prospects.